IRWD Jun 2024 2.500 call
| Previous Close | 3.8000 |
| Open | 3.8000 |
| Bid | 3.6000 |
| Ask | 5.9000 |
| Strike | 2.50 |
| Expire Date | 2024-06-21 |
| Day's Range | 3.8000 - 3.8000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 9 |
GuruFocus.comInsider Sale: Director Catherine Moukheibir Sells 80,000 Shares of Ironwood Pharmaceuticals Inc ...
On June 7, 2024, Catherine Moukheibir, a Director at Ironwood Pharmaceuticals Inc (NASDAQ:IRWD), executed a sale of 80,000 shares of the company.
Business WireIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City.
Business WireIronwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BOSTON, May 21, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 2024. B
